分支视网膜静脉阻塞患者立体视与视觉相关生活质量的关系。

Relationship between stereopsis and vision-related quality of life in patients with branch retinal vein occlusion.

机构信息

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Ophthalmology, Mito Kyodo General Hospital, Mito, Japan.

出版信息

BMJ Open Ophthalmol. 2022 Mar 3;7(1):e000925. doi: 10.1136/bmjophth-2021-000925. eCollection 2022.

DOI:10.1136/bmjophth-2021-000925

PMID:35321212

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8896036/

Abstract

BACKGROUND

To investigate the relationship between stereopsis and vision-related quality of life (VR-QOL) in patients with branch retinal vein occlusion (BRVO) before and after treatment with intravitreal ranibizumab (IVR).

METHODS

This prospective multicentred observational study included 37 patients undergoing IVR treatment for unilateral BRVO and 24 age-matched healthy controls.Stereopsis was evaluated using the TNO stereo test (TNO) and Titmus stereo test (TST) every month, and the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) was administered at baseline, then at 3, 6 and 12 months after treatment.

RESULTS

Time course of the changes in stereopsis and VR-QOL. IVR treatment significantly reduced central fovea thickness and improved both the TNO and the TST from 2 to 12 months (both p<0.05). Stereopsis before and after IVR injection in the eyes with BRVO were significantly worse than those in control subjects (TNO, p<0.001; TST, p<0.001). The VFQ-25 composite score significantly improved from 3 to 12 months after IVR treatment (p<0.05). Univariate analysis showed that the TNO score at baseline was significantly correlated with the VFQ-25 composite score at baseline and after treatment (p<0.05, p<0.05, respectively). TST score was not associated with the VFQ-25 composite score at baseline or after treatment.

CONCLUSIONS

Treatment with IVR for BRVO improved cystoid macular oedema, which was correlated to improved stereopsis, although not to the control level. The TNO score at baseline was associated with VR-QOL in patients with BRVO.

摘要

背景

研究玻璃体腔内注射雷珠单抗（IVR）治疗前后分支视网膜静脉阻塞（BRVO）患者立体视与视觉相关生存质量（VR-QOL）的关系。

方法

本前瞻性多中心观察性研究纳入了 37 例接受 IVR 单侧 BRVO 治疗的患者和 24 名年龄匹配的健康对照者。每月使用 TNO 立体测试（TNO）和Titmus 立体测试（TST）评估立体视，在基线时以及治疗后 3、6 和 12 个月时使用 25 项国立眼科研究所视功能问卷（VFQ-25）。

结果

立体视和 VR-QOL 的时间变化。IVR 治疗可显著降低中心凹视网膜厚度，从 2 至 12 个月，TNO 和 TST 均明显改善（均 p<0.05）。BRVO 眼的立体视术前和术后均明显差于对照组（TNO，p<0.001；TST，p<0.001）。IVR 治疗后 3 至 12 个月时 VFQ-25 综合评分明显改善（p<0.05）。单因素分析显示，基线时的 TNO 评分与基线和治疗后的 VFQ-25 综合评分显著相关（p<0.05，p<0.05）。TST 评分与基线或治疗后 VFQ-25 综合评分均无关。